Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)

BSE Limited (Scrip Code: 500124)

Sub: Earnings Call Notification

Please find enclosed a notification titled

"Dr. Reddy's to release Q2 FY 23 results on October 28th, 2022 Earnings call slated for October 28th @ 6:30 PM IST / 9:00

This is for your information.

For Dr. Reddy's Laboratories Limited

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

release Q2 FY 23 results on October 28th, 2022

slated for October 28th @ 6:30 PM IST / 9:00 AM EDT

Hyderabad, India, October 13th,

Dr. Reddy's Laboratories Ltd. (BSE: 500124,

NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will announce results for the second quarter ended September 30th, 2022 on

Friday, October 28th, 2022 after the Board Meeting.

Following the release, the management of

the Company will host an earnings call to discuss the Company's financial performance. (Dial In and other details given

The play back will be available after the

earnings call, till November 3rd, 2022. For play back dial in phone No: +91 22 7194 5757 | +91 22 6663 5757, and Playback

Pre-register with the below link and join

without waiting for the operator.

No password/pin number is necessary to

dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.

About Dr. Reddy's: Dr. Reddy's Laboratories

Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India.

Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of Good

Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars

and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and

dermatology. Our major markets include - USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company

with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of

the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current

ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance.

For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements

of future expectations and other forward-looking statements that are based on the management's current views and assumptions

and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially

from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the

words "may", "will", "should", "expects", "plans", "intends", "anticipates",

"believes", "estimates", "predicts", "potential", or "continue" and similar expressions

identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements

due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency

exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity

levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and

in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration

issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services

to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus

(or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission,

including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report

on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein."

The company assumes no obligation to update any information